QUÉBEC CITY, Aug. 13,
2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company") today announced that its V.P.,
Medicinal Chemistry, Matthias
Gerlach, PhD, will be making a poster presentation on
preclinical results for the Company's novel orally active
anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, during the
244th National Meeting of the American Chemistry Society
which will be held August 19-23,
2012, in Philadelphia.
Poster #46: |
|
"Dual PI3K/Erk Inhibitor AEZS-136,
A Potent Anti-Tumor Compound Under Preclinical Development
", M. Gerlach, I. Seipelt, L. Blumenstein, K.
Jung, T. Schuster, G. Mueller, E. Guenther, J. Engel and
M. Teifel. |
|
|
|
Session: |
|
General poster session / division of
medicinal chemistry; |
Dates and
time:
|
|
Sunday, August 19, 2012 from 7pm to
9pm (Eastern); and
Monday, August 20, 2012 from 8pm to 10pm (Eastern); |
Venue: |
|
Pennsylvania Convention Center, Hall
D |
About AEZS-136
AEZS-136 is an integral part of the Company's kinase research
program comprising the investigation of different compounds for
single Erk inhibition, single PI3K inhibition and
dual Erk/PI3K kinase inhibition. AEZS-136 selectively inhibits
the kinase activity of Erk 1/2 and class 1 PI3Ks, enabling
simultaneous inhibition of the Raf-Mek-Erk and the PI3K-Akt
signaling cascades. AEZS-136 was discovered using the Company's
proprietary compound library and high throughput screening
technology.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.